Le Lézard
Classified in: Health, Business
Subjects: TNM, MAT

GB Sciences Closes the Sale of GB Sciences Louisiana Cannabis Business to Wellcana Plus and Retains the Benefit of IP Developed Under GB Sciences Louisiana's Master Research and Development Agreement

The Sale, Which Immediately Eliminates Substantial Cash Obligations and Operating Expenses, Is Collateralized by Wellcana Plus's Interest in GB Sciences Louisiana.

LAS VEGAS, Nov. 18, 2019 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) completed the sale on November 15, 2019 of its 50% membership interest in GB Sciences Louisiana, LLC to Wellcana Plus, LLC, an affiliate of Wellcana Group, LLC who owns the other 50% interest.  The sale immediately eliminates current cash obligations due from GB Sciences as well as the Company's share of operating expenses going forward.  While selling the cannabis cultivation and oil production business, GB Sciences retained the benefit of Wellcana Plus's 50% interest in intellectual property developed under the Master Research and Development Agreement.

(PRNewsfoto/GB Sciences, Inc.)

The terms of the sale include a promissory note from Wellcana Plus to GB Sciences for $8 million, with payments commencing in June 2020 through December 2021.  The promissory note is secured by a pledge agreement with the 50% interest as collateral, declining pro-rata with note payments until all principal and accrued interest have been paid.  In addition to the note, there will be an earn out of $8 million from operations through the term of the Agreement for Services including renewals, if any.  The actual proceeds realized through the earn out and the timing of those proceeds will depend upon patient count accretion and the profitability of the Louisiana operations.  

John Poss, CEO of GB Sciences, stated, "We think the transaction is a win for everyone.  Wellcana Group has been an exceptional partner in Louisiana.  With the same managers, we know Wellcana Plus will lead GB Sciences Louisiana to even greater success for not only their investors but also the patients and other stakeholders in Louisiana.  For our own shareholders, the sale will greatly reduce our operating expenses while maintaining the benefit of intellectual property developed in Louisiana.  It allows us to focus on continued development of clinical cannabis formulations for which the Company has filed numerous patents, and progressing the research on our Parkinson's Disease and Chronic Neuropathic Pain formulations towards clinical trials and first-in-human pilot studies.  We believe this strategy offers tremendous opportunity to create shareholder value in this untapped segment of the cannabis sector." 

About GB Sciences, Inc.

GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development.  The Company's goal is to create safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions.  To learn more about GB Sciences, Inc.: www.gbsciences.com.

Forward-Looking Statements
This press release may contain statements relating to future results or events, which are forward-looking statements.  Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control.  It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements.  Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov.  All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Note:  Although the Company's research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.

Contact Information
GB Sciences, Inc., 3550 West Teco Ave., Las Vegas, NV 89118
866-721-0297, or 
Liz Bianco, Director of Publicity, liz@gbsciences.com


SOURCE GB Sciences, Inc.

These press releases may also interest you

at 04:10
Allied Market Research published a report, titled, "Lateral Flow Immunoassay (LFIA) Based Rapid Test Market by Application Type (Infectious Disease, Pregnancy & Fertility, Toxicology and Others), Technique type (Competitive Assay, Sandwich Assay...

at 04:05
The global knee braces market size is anticipated to reach USD 2.1 billion by 2026, according to a new report by Grand View Research, Inc. It is expected to expand at a 4.3% CAGR during the forecast period. Rising prevalence of osteoarthritis and...

at 04:00
The annual conference for the International Association of Eating Disorders Professionals (iaedptm) Foundation is only a few months away, which makes now the ideal time to register as an exhibitor to showcase your group in the iaedptm Symposium...

at 04:00
RJ Young Birmingham is proud to donate $5,250 to Children's of Alabama. Through the purchases of RJ Young equipment, donations were made in the name of Birmingham businesses to the hospital. As part of their core values, RJ Young is committed to...

at 04:00
Specialty pharmaceutical company iX Biopharma Ltd (SGX:42C) ("iX Biopharma" or, "the Company") is pleased to announce that it has successfully concluded an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) regarding Wafermine, a...

at 04:00
Kolmac Outpatient Recovery Centers is proud to announce that its Annapolis addiction treatment center will be the latest addition to its growing network of intensive outpatient (IOP) treatment locations. As of December 9th, Kolmac will provide...

News published on 18 november 2019 at 09:45 and distributed by: